The role of proteomics in depression research

Eur Arch Psychiatry Clin Neurosci. 2010 Sep;260(6):499-506. doi: 10.1007/s00406-009-0093-2. Epub 2009 Dec 9.

Abstract

Depression is a severe neuropsychiatric disorder affecting approximately 10% of the world population. Despite this, the molecular mechanisms underlying the disorder are still not understood. Novel technologies such as proteomic-based platforms are beginning to offer new insights into this devastating illness, beyond those provided by the standard targeted methodologies. Here, we will show the potential of proteome analyses as a tool to elucidate the pathophysiological mechanisms of depression as well as the discovery of potential diagnostic, therapeutic and disease course biomarkers.

MeSH terms

  • Animals
  • Antidepressive Agents / pharmacology
  • Biomarkers
  • Citalopram / pharmacology
  • Depressive Disorder* / drug therapy
  • Depressive Disorder* / genetics
  • Depressive Disorder* / metabolism
  • Depressive Disorder* / physiopathology
  • Disease Models, Animal
  • Drug Resistance
  • Humans
  • Mice
  • Nucleus Accumbens / drug effects
  • Nucleus Accumbens / metabolism
  • Nucleus Accumbens / pathology
  • Proteome / analysis
  • Proteome / genetics
  • Proteome / physiology
  • Proteomics / methods*
  • Selective Serotonin Reuptake Inhibitors / pharmacology

Substances

  • Antidepressive Agents
  • Biomarkers
  • Proteome
  • Serotonin Uptake Inhibitors
  • Citalopram